Theranostic siRNA conjugated nanoparticles: the possible central role of superparagmetic iron oxide nanoparticles as a new transfer vehicle system for therapy and diagnostic in human cancer therapy

In the past, medical research had gained enormous knowledge of relevant pathways in human carcinogenesis leading to the development of new therapeutical substances leading to an ongoing transformation of the therapeutic strategies from unspecific chemotherapy to personalized and so called precision targeting therapy (1,2). Small molecules initiated a start of a new medical era that human malignancy could come to an end. Nevertheless, the reality is quite sobering: despite the increasing possibilities to detect human cancer in early stages, due to technical possibilities in radiological imaging, the treatment success of most tumour entities lagged behind. Additionally, the overall survival rates of some tumour entities like biliary tract cancer and pancreatic cancer are still disastrous (3,4).